Castrate Resistance Articles

Articles

  • Molecular Mechanisms of Castrate-Resistant Prostate Cancer.

    Despite newer therapies for castrate-resistant prostate cancer (CRPC), many patients do not experience a treatment response, and most eventually experience secondary resistance. Various androgen-receptor-related and alternative mechanisms of resistance in CRPC have been identified.

    Published November 1, 2022
  • Targeting Glutamine Metabolism in Prostate Cancer.

    Glutamine is a conditionally essential amino acid important for cancer cell proliferation through intermediary metabolism leading to de novo synthesis of purine and pyrimidine nucleotides, hexosamine biosytnehsis, fatty acid synthesis through reductive carboxylation, maintenance of redox homeostasis, glutathione synthesis, production of non-essential amino acids, and mitochondrial oxidative phosphorylation.

    Published March 27, 2023
  • The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.

    The incidence of nonmetastatic castrate resistant prostate cancer (nmCRPC) is not well defined in contemporary practice. The aim of this study is to describe the incidence and patterns of treatment of nmCRPC over the last 6 years at a single high-volume Australian health institution.

    Published April 2, 2024